E40
Celiac Disease and Non‑Celiac Gluten Sensitivity
PreclinicalActive
Key Facts
Indication
Celiac Disease and Non‑Celiac Gluten Sensitivity
Phase
Preclinical
Status
Active
Company
About Enteralia Bioscience
Enteralia develops a novel gluten‑degrading enzyme (E40) to treat celiac disease and non‑celiac gluten sensitivity.
View full company profile